CliffBio
small molecule

ALVESCO

CICLESONIDE

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyCovis Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameALVESCO
Active ingredientCICLESONIDE
Strength0.16MG/INH
Dosage formAEROSOL, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalJanuary 2008
Marketing statusRX

Listed patents

PatentExpiresType
8371292February 2028use U-1355

More from Covis Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ALVESCO patent cliff — loss of exclusivity February 2028 | CliffBio